Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors.
Brian C ShafferMahasweta GooptuTodd E DeForMartin J MaiersJavier Bolaños-MeadeRamzi AbboudAdrienne D BriggsFarhad KhimaniDipenkumar ModiRichard A NewcombElizabeth J ShpallCaitrin BuppStephen R SpellmanHeather E StefanskiBronwen E ShawJeffrey J AulettaSteven M DevineAntonio Jimenez JimenezMonzr M Al MalkiPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Use of PTCy results in comparable OS and GRFS using either MUD or MMUD HCT, expanding access to HCT for patients from all racial and ethnic ancestry groups.